ASH 2014: Phase I study shows that inhibitor of IDH2 mutant, AG-221, induces durable remissions in IDH2-mutant acute myeloid leukaemia

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Eytan Stein (Memorial Sloan-Kettering Cancer Center, New York, NY) discusses a phase I study of AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, in IDH2-mutant acute myeloid leukaemia or pre-leukeamia (including myelodysplastic syndromes, chronic myelomonocytic leukeamia, and myeloproliferative neoplasms).